Cullinan Therapeutics Insider Sells 8,000 Shares at $21.57

Jennifer Michaelson, an insider at Cullinan Therapeutics (NASDAQ:CGEM), sold 8,000 shares on September 8 at an average price of $21.57. The transaction totaled $172,560 and reduced her total holding to 158,844 shares, valued at approximately $3.43 million. This sale represents a 4.79% decrease in her ownership stake in the biotechnology firm.

The latest divestiture follows two previous sales this year. On August 13, Michaelson sold 30,000 shares at $20.26 per share, generating $607,800. Earlier, on July 6, she sold another 8,000 shares at $17.82 each for a total of $142,560. These moves indicate a consistent pattern of reducing personal exposure to the company’s equity over the last three months.

Recent Stock Performance Metrics

Cullinan Therapeutics shares traded down $0.60 to $20.71 during midday trading on Thursday, marking a 2.8% decline. The day’s volume of 188,454 shares was significantly below the average of 855,504. The company currently holds a market capitalization of $1.33 billion. Its 50-day simple moving average stands at $19.33, while the 200-day average is $16.33, placing the current price above both technical indicators.

The stock has a beta of 0.02, indicating low volatility relative to the broader market. The one-year trading range spans from a low of $5.68 to a high of $23.19. With a negative P/E ratio of -6.70, the company remains unprofitable, a common characteristic for clinical-stage biotechs focused on development rather than immediate revenue generation.

Quarterly Earnings Miss Expectations

Cullinan Therapeutics reported its most recent quarterly results on August 6. The company posted an earnings per share (EPS) of negative $0.81, missing the consensus estimate of negative $0.80 by $0.01. For the current fiscal year, analysts forecast an EPS of negative $3.08. The slight miss in the quarterly report reflects the ongoing costs associated with the company’s therapeutic pipeline and operational expenses.

Analyst Ratings And Targets

Market sentiment regarding Cullinan Therapeutics remains mixed. According to data aggregated by GN stocks/nasdaq, the consensus rating is a "Moderate Buy" with an average price target of $32.86. Recent actions include Wedbush raising its target to $42.00 with an "Outperform" rating on August 13, and BTIG Research increasing its target to $39.00 with a "Buy" rating on July 29. Conversely, Weiss Ratings maintained a "Sell" rating, and Wall Street Zen moved its rating from "Sell" to "Hold" in early September.

Institutional investors have also adjusted their positions. Jane Street Group LLC increased its holdings by 145.9% in the first quarter, acquiring an additional 109,413 shares to reach a total of 34,396 shares worth approximately $260,000. Creative Planning boosted its stake by 222.2% in the second quarter, adding 28,773 shares to a total position of 41,723 shares valued at $314,000. These institutional moves suggest continued interest despite the insider selling activity.